SCHEMBL4453007

SCHEMBL4453007

CNC(=O)C(NC(=O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1)c1ccccc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
TACR1 P25103 3/20 0.38
CNR2 P34972 2/20 0.38
TACR3 P29371 2/20 0.38
MTTP P55157 1/20 0.37
MMP1 P03956 1/20 0.37
MMP13 P45452 1/20 0.37
ROCK2 O75116 1/20 0.37
CNR1 P21554 1/20 0.37
TRPV1 Q8NER1 3/20 0.36
TAS1R3 Q7RTX0 2/20 0.36
TAS1R1 Q7RTX1 2/20 0.36
P2RX1 P51575 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4453004 1.00 NPSR1 (0.40) NPSR1HDAC3HDAC6CYP1A2CYP3A4
SCHEMBL4448204 0.80 MTTP (0.52) HDAC3HDAC6TACR1TACR3MTTP
SCHEMBL4448206 0.80 MTTP (0.52) HDAC3HDAC6TACR1TACR3MTTP
SCHEMBL4446727 0.76 ANPEP (0.46) HDAC3HDAC6MTTP
SCHEMBL4446731 0.76 ANPEP (0.46) HDAC3HDAC6MTTP
SCHEMBL4447357 0.76 ANPEP (0.46) HDAC3HDAC6MTTP
SCHEMBL4452601 0.71 L3MBTL1 (0.44) HDAC3HDAC6TACR1TACR3MTTP
SCHEMBL4452596 0.71 L3MBTL1 (0.44) HDAC3HDAC6TACR1TACR3MTTP
SCHEMBL4456942 0.71 TACR1 (0.49) NPSR1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL4450893 0.69 CA1 (0.46) HDAC3HDAC6TACR1TACR3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012010-A1 Amino acid derivatives as calcium channel blockers CACNA1G, CACNA1H, CACNA1I NPSR1 727/4885HDAC3 3823/4885HDAC6 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.